outcome is incident coronary artery disease. Participants are free of coronary artery disease at the start of the study and randomized to receive either the new medication or a placebo. Participants are followed for a maximum of 10 years for the development of coronary artery disease.
The following data are:
Number participants Number with coronary artery disease
Cholesterol medication 400 28
Placebo 400 42
Compute the Relative Risk of coronary artery disease in patients receiving the new medication as compared to placebo.
Relative Risk =
Compute the Odd ratio of coronary artery disease in patients receiving the new medications as compared to placebo
Odds Ratio =
Hi there! Click one of our representatives below and we will get back to you as soon as possible.